AU2010277688B2 - Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases - Google Patents
Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases Download PDFInfo
- Publication number
- AU2010277688B2 AU2010277688B2 AU2010277688A AU2010277688A AU2010277688B2 AU 2010277688 B2 AU2010277688 B2 AU 2010277688B2 AU 2010277688 A AU2010277688 A AU 2010277688A AU 2010277688 A AU2010277688 A AU 2010277688A AU 2010277688 B2 AU2010277688 B2 AU 2010277688B2
- Authority
- AU
- Australia
- Prior art keywords
- lower alkyl
- amino
- formula
- compound
- lower alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166469 | 2009-07-27 | ||
| EP09166469.8 | 2009-07-27 | ||
| PCT/EP2010/060803 WO2011012577A1 (en) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010277688A1 AU2010277688A1 (en) | 2012-02-09 |
| AU2010277688B2 true AU2010277688B2 (en) | 2013-12-05 |
Family
ID=41226617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010277688A Ceased AU2010277688B2 (en) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8802858B2 (enExample) |
| EP (1) | EP2459553B1 (enExample) |
| JP (1) | JP5576485B2 (enExample) |
| KR (1) | KR101758400B1 (enExample) |
| CN (1) | CN102471329B (enExample) |
| AU (1) | AU2010277688B2 (enExample) |
| BR (1) | BR112012001817B8 (enExample) |
| CA (1) | CA2767875C (enExample) |
| CY (1) | CY1115809T1 (enExample) |
| DK (1) | DK2459553T3 (enExample) |
| EA (1) | EA021380B1 (enExample) |
| ES (1) | ES2524119T3 (enExample) |
| HR (1) | HRP20141120T1 (enExample) |
| IL (1) | IL217195A (enExample) |
| MX (1) | MX336240B (enExample) |
| NZ (1) | NZ597376A (enExample) |
| PL (1) | PL2459553T3 (enExample) |
| PT (1) | PT2459553E (enExample) |
| RS (1) | RS53679B1 (enExample) |
| SI (1) | SI2459553T1 (enExample) |
| TW (1) | TWI457337B (enExample) |
| UA (1) | UA106763C2 (enExample) |
| WO (1) | WO2011012577A1 (enExample) |
| ZA (1) | ZA201200228B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012098203A1 (en) | 2011-01-21 | 2012-07-26 | Basilea Pharmaceutica Ag | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
| JP6302674B2 (ja) * | 2011-01-21 | 2018-03-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用 |
| US10222377B2 (en) | 2011-01-21 | 2019-03-05 | Basilea Pharmaceutica Ag | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles |
| JP6295081B2 (ja) * | 2011-02-24 | 2018-03-14 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用 |
| JP6334393B2 (ja) | 2011-03-29 | 2018-05-30 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 薬物応答のバイオマーカーとしてのホスホＡｋｔの使用 |
| US9558575B2 (en) | 2012-02-28 | 2017-01-31 | Blackberry Limited | Methods and devices for selecting objects in images |
| ITRM20130248A1 (it) * | 2013-04-24 | 2014-10-25 | Medivis S R L | Formulazioni di riboflavina per il cross-linking transepiteliale. |
| WO2015173341A1 (en) * | 2014-05-13 | 2015-11-19 | Basilea Pharmaceutica Ag | Dosage principle for anti-cancer furazanylbenzimidazoles |
| HK1257768A1 (zh) * | 2015-10-22 | 2019-10-25 | Basilea Pharmaceutica International AG | Eb1作为药物应答的生物标记物的用途 |
| JP2020517608A (ja) * | 2017-04-20 | 2020-06-18 | ピーアイ インダストリーズ リミテッドＰｉ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ | 新規フェニルアミン化合物 |
| CA3058695A1 (en) * | 2017-04-26 | 2018-11-01 | Basilea Pharmaceutica International AG | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
| EP3624790A1 (en) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20220031670A1 (en) | 2018-09-20 | 2022-02-03 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004103994A1 (en) * | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| EP1723138B1 (en) * | 2004-02-11 | 2010-07-14 | Basilea Pharmaceutica AG | Substituted benzimidazoles and their use for inducing apoptosis |
-
2010
- 2010-07-26 KR KR1020127005138A patent/KR101758400B1/ko not_active Expired - Fee Related
- 2010-07-26 CA CA2767875A patent/CA2767875C/en active Active
- 2010-07-26 RS RS20140669A patent/RS53679B1/sr unknown
- 2010-07-26 JP JP2012522131A patent/JP5576485B2/ja not_active Expired - Fee Related
- 2010-07-26 SI SI201030829T patent/SI2459553T1/sl unknown
- 2010-07-26 ES ES10740196.0T patent/ES2524119T3/es active Active
- 2010-07-26 EA EA201200189A patent/EA021380B1/ru unknown
- 2010-07-26 US US13/384,467 patent/US8802858B2/en active Active
- 2010-07-26 CN CN201080033104.2A patent/CN102471329B/zh not_active Expired - Fee Related
- 2010-07-26 MX MX2012000611A patent/MX336240B/es unknown
- 2010-07-26 AU AU2010277688A patent/AU2010277688B2/en not_active Ceased
- 2010-07-26 EP EP10740196.0A patent/EP2459553B1/en active Active
- 2010-07-26 WO PCT/EP2010/060803 patent/WO2011012577A1/en not_active Ceased
- 2010-07-26 PT PT107401960T patent/PT2459553E/pt unknown
- 2010-07-26 PL PL10740196T patent/PL2459553T3/pl unknown
- 2010-07-26 NZ NZ597376A patent/NZ597376A/en not_active IP Right Cessation
- 2010-07-26 DK DK10740196.0T patent/DK2459553T3/da active
- 2010-07-26 UA UAA201201704A patent/UA106763C2/uk unknown
- 2010-07-26 BR BR112012001817A patent/BR112012001817B8/pt active IP Right Grant
- 2010-07-26 HR HRP20141120AT patent/HRP20141120T1/hr unknown
- 2010-07-27 TW TW099124742A patent/TWI457337B/zh active
-
2011
- 2011-12-25 IL IL217195A patent/IL217195A/en active IP Right Grant
-
2012
- 2012-01-11 ZA ZA2012/00228A patent/ZA201200228B/en unknown
-
2014
- 2014-12-03 CY CY20141101010T patent/CY1115809T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004103994A1 (en) * | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2767875C (en) | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | |
| ES2405054T3 (es) | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato | |
| US7951957B2 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| AU2007334436A1 (en) | Novel oxadiazole compounds | |
| US8404672B2 (en) | Substituted heterocyclic compounds | |
| CN112778302A (zh) | 一种kras g12c抑制剂化合物及其用途 | |
| CA2526026C (en) | Furazanobenzimidazoles | |
| CN113831301A (zh) | 苯并噻唑类衍生物及其用途 | |
| JP2025518592A (ja) | 二環式誘導体ｐａｒｐ阻害剤及びその用途 | |
| CN113321640A (zh) | 一种吲哚类化合物及其应用 | |
| HK1166316B (en) | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | |
| CN116283920B (zh) | 2,4-二取代吡啶类化合物及其应用 | |
| CN118047779A (zh) | 含苯联杂芳基的二氢喋啶酮衍生物及其用途 | |
| CA3145776A1 (en) | Aryl-n-aryl derivatives for treating an rna virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |